Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

IMAB In-licenses Asia Rights to Anti-Immunology Drug

publication date: Dec 20, 2016
IMAB, a Shanghai biotech, in-licensed Asian rights to an IL-6 antagonist from Ferring Pharma of Switzerland. Olamkicept (pINN), which has completed a Phase I trial, is intended for immunological indications including inflammatory bowel diseases and rheumatoid arthritis. IMAB's commitment to fund further development of olamkicept in Asia seems to be the only upfront financial consideration. IMAB has an option to acquire global rights to the candidate, though further details of the agreement were not disclosed. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital